Maintenance Selinexor May Boost PFS in TP53 Wild-Type Advanced Endometrial Cancer
(MedPage Today) -- SEOUL, South Korea -- Maintenance therapy with selinexor (Xpovio) seemed to substantially extend progression-free survival (PFS) in patients with wild-type TP53 advanced or recurrent endometrial cancer, according to data from... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 5, 2023 Category: Hematology Source Type: news
Adding Atezolizumab Improves Survival in Advanced Cervical Cancer
(MedPage Today) -- First-line treatment with the anti-PD-L1 inhibitor atezolizumab (Tecentriq) combined with bevacizumab (Avastin) and platinum-based chemotherapy significantly improved survival in patients with metastatic or recurrent cervical... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 3, 2023 Category: Hematology Source Type: news
Wearables as Cancer Monitors; No China Price Break; Cancer Mystery in Appalachia
(MedPage Today) -- Wearable devices have the potential to become major contributors to precision cancer care. (UVA Health)
Biological therapy -- such as monoclonal antibodies and antibody-drug conjugates -- dominates the therapeutic landscape... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 3, 2023 Category: Hematology Source Type: news
Transitioning Cancer Survivors Away From Oncologic Care
(MedPage Today) -- October was Breast Cancer Awareness month and the sudden influx of pink in our homes, on our televisions, in our workplaces, and in local businesses reminded us that we still lose far too many of our loved ones to cancer, not... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 3, 2023 Category: Hematology Source Type: news
False-Positive Mammograms May Indicate Higher Breast Cancer Risk in the Future
(MedPage Today) -- Women with a false-positive mammography result have an increased risk of developing breast cancer over the following 20 years, according to a large population-based cohort study from Sweden.
In the cohort of nearly 500,000 women... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 2, 2023 Category: Hematology Source Type: news
Years of Progressing Facial Numbness and Deteriorating Vision Drives Diagnosis
(MedPage Today) -- Suspect perineural recurrence of cutaneous squamous cell carcinoma, experts urge (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 2, 2023 Category: Hematology Source Type: news
Lambert-Eaton Myasthenic Syndrome Underdiagnosed Alongside SCLC in the U.S.
(MedPage Today) -- PHOENIX -- While Lambert-Eaton myasthenic syndrome (LEMS) is known to be associated with small cell lung cancer (SCLC), researchers here suggested the autoimmune disorder is underdiagnosed in the U.S.
Using claims from a large... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 2, 2023 Category: Hematology Source Type: news
ACS: Millions More Should Get Lung Cancer Screening
(MedPage Today) -- The American Cancer Society (ACS) widened the pool of past and current smokers eligible for lung cancer screening in its new guideline recommendations, potentially opening the door to 5 million more U.S. adults.
Annual lung... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 2, 2023 Category: Hematology Source Type: news
Reduced-Dose Schedule of Cabazitaxel Viable for Seniors With mCRPC
(MedPage Today) -- A reduced-dose schedule of cabazitaxel (Jevtana) plus prophylactic granulocyte colony-stimulating factor (G-CSF) should be offered to older men with metastatic castration-resistant prostate cancer (mCRPC), according to results... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 1, 2023 Category: Hematology Source Type: news
The Exciting Potential of Antibody-Drug Conjugates in Lung Cancer
(MedPage Today) -- MedPage Today brought together three expert leaders for a virtual roundtable discussion on lung cancer: Moderator Roy Herbst, MD, PhD, was joined by Anne Chiang, MD, PhD, and So Yeon Kim, MD, all from the Yale Cancer Center in... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 31, 2023 Category: Hematology Source Type: news
Radionuclide Therapy Tops AR-Pathway Inhibitor Switch for mCRPC
(MedPage Today) -- MADRID -- Radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) doubled when patients received a radionuclide ligand targeting prostate-specific membrane antigen (PSMA) instead... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 25, 2023 Category: Hematology Source Type: news
New Options Challenge Standard Treatments in EGFR-Mutant NSCLC
(MedPage Today) -- MADRID -- Two positive phase III trials involving amivantamab (Rybrevant)-based regimens introduced new first- and second-line options in EGFR-mutant non-small cell lung cancer (NSCLC), though toxicity with the combination... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 25, 2023 Category: Hematology Source Type: news
ALK Inhibitor Outperforms Adjuvant Chemotherapy for Resected Lung Cancer
(MedPage Today) -- MADRID -- Disease-free survival (DFS) in resectable ALK-positive non-small cell lung cancer (NSCLC) improved by 76% with adjuvant alectinib (Alecensa) compared with chemotherapy, according to a randomized trial.
Across disease... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 24, 2023 Category: Hematology Source Type: news
Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers
(MedPage Today) -- MADRID -- Treatment with an investigational TROP2-directed antibody-drug conjugate (ADC) significantly improved progression-free survival (PFS) in patients with previously treated metastatic breast cancer and non-small cell... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 24, 2023 Category: Hematology Source Type: news
Randomized Trial Backs HIF-2a Inhibition in Advanced RCC
(MedPage Today) -- MADRID -- Treatment with the hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan (Welireg) in advanced, heavily pretreated kidney cancer led to superior outcomes when compared with an older kinase inhibitor... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 24, 2023 Category: Hematology Source Type: news
